Latest news

Debiopharm’s new agreement with the University of Geneva boosts scientific Innovation Hub in the Lemanic region of Switzerland through the…

Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124

7e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Debiopharm leads investment round for evidence-based digital cancer therapeutic app Mika to empower cancer patients

VivoSense Announces Closing of $25M Series A Financing Round Co-led by Xontogeny and Debiopharm

Challenge pour la Qualité de vie du patient 2022 : l’appel à projets est ouvert !

Debiopharm and Aspen Partner to Launch Prostate Cancer Drug Trelstar® in South Africa

Debiopharm invests in VeriSIM Life’s $15m series A round to advance AI-enabled drug research

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study